Speaker
Summary
Introduction
Nanoparticles (NPs) are an attractive platform for radionuclide delivery that have the potential to overcome the limitations of radionuclide self-targeting and chelation. For α-emitting radionuclides, such as 225Ac, 212Pb/212Bi, or 223Ra, the α-particle bond-breaking recoil energy and subsequent relocation of decay daughters may result in increased off-target effects. Encapsulation and retention of α-emitting radionuclides and their decay daughters has been demonstrated in vitro, but further development is required to optimize their efficacy and delivery.
Description of the Work
We have synthesized and evaluated different approaches to radio-NPs using both inorganic and organic platforms. In particular, we have evaluated poly(lactic-co-glycolic acid) (PLGA) organic NPs as biodegradable and biocompatible delivery vehicles for radionuclide retention and targeted delivery. These have been fully characterized using a variety of mass spectrometry techniques, cryogenic electron microscopy, and cell-based assays. Similarly, we have employed lanthanide-based inorganic NPs to encapsulate different surrogate isotopes and radionuclides. Understanding the interaction of radionuclides with lanthanide-based NPs is critical to optimize their encapsulation and retention. Improving colloidal stability, biocompatibility, and targeting of NPs represents a key step toward the development of radionanomedicines.
Conclusions
Our application of nanotechnology and advanced characterization techniques to design and understand radionuclide doped nanomedicines offers a unique approach for theranostics and future combination therapies. Recent research in this area will be discussed.
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
